What question did this study set out to answer?

Summarize the role of MGMT promoter methylation in mediating resistance to alkylating chemotherapy in glioblastoma and evaluate emerging clinical strategies to modulate MGMT activity.

September 1, 2008Journal of Clinical OncologyOpen Access

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

View Full Paper

Ask AI

Bookmark

Authors

MHMonika E. HegiUniversity Hospital of Lausanne LLLili LiuSoochow University JHJames G. HermanOntario Institute for Cancer Research

Discussion

Member takes

Implication

Review reveals MGMT promoter methylation predicts survival in glioblastoma, highlighting therapeutic approaches to overcome alkylator resistance.

Key Points

Summarize the role of MGMT promoter methylation in mediating resistance to alkylating chemotherapy in glioblastoma and evaluate emerging clinical strategies to modulate MGMT activity.
Synthesized clinical and mechanistic evidence on MGMT expression, epigenetic silencing by promoter methylation, and patient outcomes following alkylating agent therapy in malignant glioma.
Evaluated resistance-modulating approaches, including MGMT pseudosubstrate inhibitors (such as O6-benzylguanine), RNA interference-mediated gene silencing, and dose-dense temozolomide schedules.
Epigenetic silencing of MGMT via promoter methylation strongly correlates with prolonged progression-free and overall survival in patients treated with alkylating agents.
Systemic administration of MGMT pseudosubstrate inhibitors increases hematologic toxicity, while the clinical efficacy and intratumoral depletion capacity of dose-dense temozolomide remain uncertain.
Tumor recurrence eventually occurs even in patients with MGMT promoter methylation, emphasizing the persistent challenge of alkylator resistance in malignant glioma.

Cite This Study

Hegi et al. (2008) studied this question.

synapsesocial.com/papers/69da07ed0f32475823a3cbb4 https://doi.org/10.1200/jco.2007.11.5964

View Full Paper

Ask AI

Bookmark

Implication

Review reveals MGMT promoter methylation predicts survival in glioblastoma, highlighting therapeutic approaches to overcome alkylator resistance.

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Discussion

Member takes

Implication

Key Points

Cite This Study

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider